Xynomic Pharmaceutical Holdings Inc. (XYNO)
Jun 17, 2021 - XYNO was delisted (reason: merged with Xu-Nuo Pharma)
Stock Price: $2.22 USD
0.00 (0.00%)
Updated Jun 16, 2021 9:30 AM EDT
| Market Cap | 102.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.80M |
| Shares Out | 46.27M |
| EPS (ttm) | -4.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Jul 29, 2021 |
| Last Price | $2.22 |
| Previous Close | $2.22 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 2.22 |
| Day's Range | 2.22 - 2.22 |
| Day's Volume | 0 |
| 52-Week Range | 0.20 - 3.79 |
News
There are no news available yet.
About XYNO
Xynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma ... [Read more...]
| Industry Biotechnology | Founded 2016 |
| Stock Exchange OTCMKTS | Ticker Symbol XYNO |